BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 26445140)

  • 1. Characterization of the relationship between dose and blood eosinophil response following subcutaneous administration of mepolizumab.
    Pouliquen IJ; Kornmann O; Barton SV; Price JA; Ortega HG
    Int J Clin Pharmacol Ther; 2015 Dec; 53(12):1015-27. PubMed ID: 26445140
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Weight-adjusted Intravenous Reslizumab in Severe Asthma with Inadequate Response to Fixed-Dose Subcutaneous Mepolizumab.
    Mukherjee M; Aleman Paramo F; Kjarsgaard M; Salter B; Nair G; LaVigne N; Radford K; Sehmi R; Nair P
    Am J Respir Crit Care Med; 2018 Jan; 197(1):38-46. PubMed ID: 28915080
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical efficacy and safety of mepolizumab (SB-240563), a humanized monoclonal antibody to IL-5, in cynomolgus monkeys.
    Hart TK; Cook RM; Zia-Amirhosseini P; Minthorn E; Sellers TS; Maleeff BE; Eustis S; Schwartz LW; Tsui P; Appelbaum ER; Martin EC; Bugelski PJ; Herzyk DJ
    J Allergy Clin Immunol; 2001 Aug; 108(2):250-7. PubMed ID: 11496242
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics and pharmacodynamics of mepolizumab, an anti-interleukin-5 monoclonal antibody.
    Smith DA; Minthorn EA; Beerahee M
    Clin Pharmacokinet; 2011 Apr; 50(4):215-27. PubMed ID: 21348536
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blood eosinophil count is a useful biomarker to identify patients with severe eosinophilic asthma.
    Katz LE; Gleich GJ; Hartley BF; Yancey SW; Ortega HG
    Ann Am Thorac Soc; 2014 May; 11(4):531-6. PubMed ID: 24606022
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and pharmacodynamics of mepolizumab, an anti-interleukin 5 monoclonal antibody, in healthy Japanese male subjects.
    Tsukamoto N; Takahashi N; Itoh H; Pouliquen I
    Clin Pharmacol Drug Dev; 2016 Mar; 5(2):102-8. PubMed ID: 27138023
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mepolizumab: 240563, anti-IL-5 monoclonal antibody - GlaxoSmithKline, anti-interleukin-5 monoclonal antibody - GlaxoSmithKline, SB 240563.
    Drugs R D; 2008; 9(2):125-30. PubMed ID: 18298130
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An antibody against IL-5 reduces numbers of esophageal intraepithelial eosinophils in children with eosinophilic esophagitis.
    Assa'ad AH; Gupta SK; Collins MH; Thomson M; Heath AT; Smith DA; Perschy TL; Jurgensen CH; Ortega HG; Aceves SS
    Gastroenterology; 2011 Nov; 141(5):1593-604. PubMed ID: 21835135
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mepolizumab Attenuates Airway Eosinophil Numbers, but Not Their Functional Phenotype, in Asthma.
    Kelly EA; Esnault S; Liu LY; Evans MD; Johansson MW; Mathur S; Mosher DF; Denlinger LC; Jarjour NN
    Am J Respir Crit Care Med; 2017 Dec; 196(11):1385-1395. PubMed ID: 28862877
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway.
    Flood-Page PT; Menzies-Gow AN; Kay AB; Robinson DS
    Am J Respir Crit Care Med; 2003 Jan; 167(2):199-204. PubMed ID: 12406833
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term safety and pharmacodynamics of mepolizumab in children with severe asthma with an eosinophilic phenotype.
    Gupta A; Ikeda M; Geng B; Azmi J; Price RG; Bradford ES; Yancey SW; Steinfeld J
    J Allergy Clin Immunol; 2019 Nov; 144(5):1336-1342.e7. PubMed ID: 31425781
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rapid and Consistent Improvements in Morning PEF in Patients with Severe Eosinophilic Asthma Treated with Mepolizumab.
    Ortega H; Menzies-Gow A; Llanos JP; Forshag M; Albers F; Gunsoy N; Bradford ES; Yancey SW; Kraft M
    Adv Ther; 2018 Jul; 35(7):1059-1068. PubMed ID: 29949045
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma.
    Flood-Page P; Swenson C; Faiferman I; Matthews J; Williams M; Brannick L; Robinson D; Wenzel S; Busse W; Hansel TT; Barnes NC;
    Am J Respir Crit Care Med; 2007 Dec; 176(11):1062-71. PubMed ID: 17872493
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma.
    Khatri S; Moore W; Gibson PG; Leigh R; Bourdin A; Maspero J; Barros M; Buhl R; Howarth P; Albers FC; Bradford ES; Gilson M; Price RG; Yancey SW; Ortega H
    J Allergy Clin Immunol; 2019 May; 143(5):1742-1751.e7. PubMed ID: 30359681
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia.
    Nair P; Pizzichini MM; Kjarsgaard M; Inman MD; Efthimiadis A; Pizzichini E; Hargreave FE; O'Byrne PM
    N Engl J Med; 2009 Mar; 360(10):985-93. PubMed ID: 19264687
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-interleukin-5 antibody treatment (mepolizumab) in active eosinophilic oesophagitis: a randomised, placebo-controlled, double-blind trial.
    Straumann A; Conus S; Grzonka P; Kita H; Kephart G; Bussmann C; Beglinger C; Smith DA; Patel J; Byrne M; Simon HU
    Gut; 2010 Jan; 59(1):21-30. PubMed ID: 19828470
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Subcutaneous mepolizumab in children aged 6 to 11 years with severe eosinophilic asthma.
    Gupta A; Pouliquen I; Austin D; Price RG; Kempsford R; Steinfeld J; Bradford ES; Yancey SW
    Pediatr Pulmonol; 2019 Dec; 54(12):1957-1967. PubMed ID: 31502421
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mepolizumab for the treatment of severe eosinophilic asthma.
    Poulakos MN; Cargill SM; Waineo MF; Wolford AL
    Am J Health Syst Pharm; 2017 Jul; 74(13):963-969. PubMed ID: 28645995
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mepolizumab: First Global Approval.
    Keating GM
    Drugs; 2015 Dec; 75(18):2163-9. PubMed ID: 26603873
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of patients with the hypereosinophilic syndrome with mepolizumab.
    Rothenberg ME; Klion AD; Roufosse FE; Kahn JE; Weller PF; Simon HU; Schwartz LB; Rosenwasser LJ; Ring J; Griffin EF; Haig AE; Frewer PI; Parkin JM; Gleich GJ;
    N Engl J Med; 2008 Mar; 358(12):1215-28. PubMed ID: 18344568
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.